This case stems from a licensing dispute over standard essential patents (SEPs) for video and communication technologies. InterDigital asserts ownership of multiple SEPs covering video streaming and wireless communication technologies, alleging that Amazon's Prime Video service, CloudFront content delivery network, and Fire series devices implement its patented technologies. After licensing negotiations failed, the dispute spread across multiple jurisdictions.

The six organizations involved are the Intellectual Property Innovation Alliance (IP2Innovate), the European Automobile Manufacturers Association (ACEA), the Application Technology Association (ACT), the Computer & Communications Industry Association Europe (CCIA Europe), the European Association of Automotive Suppliers (CLEPA), and the Fair Standards Alliance (FSA). Representing over 100 member companies across automotive, IT, semiconductors, artificial intelligence, and consumer goods sectors, these organizations collectively hold more than 580,000 patents within the EU and employ approximately 2.5 million people.

Recently, the UPC District Court in The Hague ruled in favor of Abbott Diabetes Care (hereinafter referred to as Abbott) in its infringement case against MicroTech (MicroTech Medical Devices (Hangzhou) Co., Ltd., hereinafter referred to as MicroTech Medical), Lotus NL, Mediq, and other companies, granting a preliminary injunction against the defendants. The court further determined that the patent holder's 2.5-month period between completing test purchases and filing the application satisfied the urgency requirement for interim measures.

On March 3, 2026, the Hague Division of the Unified Patent Court (UPC) recently issued a final judgment in the patent infringement case brought by Advanced Brain Monitoring (hereinafter referred to as “ABM”) against Philips.

The AI copyright dispute originated with computer scientist Stephen Thaler, who sought copyright registration for a visual artwork titled A Recent Entrance to Paradise, created by his self-developed AI system DABUS. Thaler listed the AI as the author in the application.

According to the ruling, the ITC upheld its prior infringement determination and issued a Limited Exclusion Order and Cease and Desist Order against Insta360. These orders prohibit Insta360 from continuing to import, sell, or promote the infringing products within the United States. Both orders will take effect after completion of the Presidential review process.

Recently, in its patent dispute with InterDigital, Amazon was found by the Mannheim Regional Division of the Unified Patent Court (UPC) to have violated an anti-interference injunction (AII)*. The company made a court commitment during the hearing, thereby avoiding a potential fine of up to 50 million euros (approximately 404 million yuan).

Nokia's approach to proposing interim licensing mirrors Huawei's strategy in securing a successful interim license declaration against TP-Link in the UK High Court. When patent holders proactively accept court-determined rates, licensees who previously actively sought UK judicial relief may hesitate. For them, interim licensing shifts from leverage against Nokia to a potential court ruling that could determine their global royalty rates.

According to the public complaint, Amazon's Prime Video streaming service, CloudFront content delivery network service, and Fire series terminal devices implement the patented technical solutions in their content caching, request routing, edge node management, and data distribution mechanisms. These implementations fall within the scope of the relevant patent claims. Therefore, InterDigital requests the court to find Amazon liable for patent infringement and order it to bear corresponding damages.

Recently, Bayer Healthcare (hereinafter referred to as “Bayer”) filed a lawsuit in the U.S. District Court for the Southern District of New York against Johnson & Johnson (hereinafter referred to as “Johnson & Johnson”) and its subsidiary Janssen Biotech. In the lawsuit, Bayer alleges that Johnson & Johnson engaged in false advertising using research data that does not meet FDA standards. Bayer is seeking an immediate court order to halt the relevant advertising and is pursuing damages.